source
- Gilead reports positive Phase 2 results for oral ulcerative colitis drugGilead announced that its experimental oral therapy for ulcerative colitis achieved positive results in a Phase 2 trial. The study reported that patients receiving the drug showed measurable clini…
- Nouscom secures $135 million Series D to advance lead cancer vaccine into Phase 2Clinical-stage biotech Nouscom announced it has closed a $135 million Series D financing round that was oversubscribed. The capital will be used to move its lead cancer vaccine candidate into a Pha…